Header Logo

Connection

Kyle Amber to Pneumonia, Pneumocystis

This is a "connection" page, showing publications Kyle Amber has written about Pneumonia, Pneumocystis.
Connection Strength

4.222
  1. Development of Pneumocystis pneumonia in a patient receiving both rituximab and IVIg for pemphigus vulgaris. J Dtsch Dermatol Ges. 2022 04; 20(4):520-521.
    View in: PubMed
    Score: 0.781
  2. The risk of Pneumocystis pneumonia in patients of?autoimmune blistering disease-reply to letter entitled "Pemphigus management guidelines: A life-saving perspective". J Am Acad Dermatol. 2021 11; 85(5):e289.
    View in: PubMed
    Score: 0.745
  3. Disease-dependent Risk of Pneumocystis Pneumonia: The Case of Autoimmune Blistering Disease. Chest. 2020 12; 158(6):2704-2705.
    View in: PubMed
    Score: 0.714
  4. Dapsone, 2 birds with 1 stone: A response to "Dapsone advantages over trimethoprim-sulfamethoxazole for Pneumocystis pneumonia prophylaxis in immunobullous patients". J Am Acad Dermatol. 2021 12; 85(6):e369.
    View in: PubMed
    Score: 0.638
  5. Comment on "Incidence of pneumocystosis among patients exposed to immunosuppression". J Am Acad Dermatol. 2019 08; 81(2):e47.
    View in: PubMed
    Score: 0.635
  6. Determining the Incidence of Pneumocystis Pneumonia in Patients With Autoimmune Blistering Diseases Not Receiving Routine Prophylaxis. JAMA Dermatol. 2017 11 01; 153(11):1137-1141.
    View in: PubMed
    Score: 0.576
  7. Balancing the risks and benefits of prophylaxis: a reply to "Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions". Int J Dermatol. 2017 01; 56(1):e4-e5.
    View in: PubMed
    Score: 0.133
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.